MicroPort CardioFlow Medtech Corp. (HK:2160) has released an update.
MicroPort CardioFlow Medtech Corporation reports a promising interim revenue of RMB 215-225 million for the first half of 2024, marking a significant increase of 22-28% from the previous year. This surge is credited to the successful expansion of their TAVI products in China, the launch of the AnchorMan system, and increased international sales, including new market entries and obtaining the CE certificate in Europe. The company also emphasizes its strategic focus on resource allocation, advancing key projects, and stringent cost control measures aimed at achieving operational breakeven.
For further insights into HK:2160 stock, check out TipRanks’ Stock Analysis page.
